K-CAB Expected to Win FDA Approval in January Next Year
Zacubo Aims for U.S. Launch in 2029
U.S. P-CAB Prices Dozens of Times Higher Than PPIs
“A Strategy to Attract Mild Patients Is Needed”

Pharmaceutical companies that have rapidly reshaped the domestic gastroesophageal reflux disease (GERD) treatment market with the introduction of potassium-competitive acid blockers (P-CAB) are now turning their attention to the United States, the world’s largest pharmaceutical market. The potential sales of the U.S. P-CAB market are estimated at 2 billion dollars (approximately 3 trillion won). However, since inexpensive generic proton pump inhibitors (PPIs) still dominate prescriptions and insurance coverage requirements are stringent, experts point out that a different market strategy is required compared to Korea.


K-Drugs Eyeing $2 Billion US P-CAB Market... The Battleground Is 'Drug Pricing' View original image

According to industry sources on September 30, HK inno.N’s U.S. partner, Braintree, submitted a new drug application (NDA) for “K-CAB” (active ingredient: tegoprazan) to the U.S. Food and Drug Administration (FDA) in January. The application covers three indications: non-erosive reflux disease (NERD), erosive esophagitis (EE), and maintenance therapy following EE treatment. Approval is expected by January next year. If all goes according to plan, HK inno.N will be the first among Korean-developed P-CABs to enter the U.S. market.


Onconic Therapeutics has also begun efforts to launch “Zacubo” (active ingredient: zasaprazan) in the U.S. Discussions with the FDA on Phase 3 clinical trial design are ongoing, with plans to submit an investigational new drug (IND) application within this year, aiming for a local launch in 2029. Meanwhile, Daewoong Pharmaceutical’s “Fexuclu” (active ingredient: fexuprazan) and “Padoprazan,” which is being co-developed by Daewon Pharmaceutical and IlDong Pharmaceutical, are seeking local partners for entry into the U.S. market.


Currently, the U.S. P-CAB market is effectively being pioneered by “Voquezna,” the only product approved and being sold following FDA authorization. According to the manufacturer, Phathom Pharmaceuticals (Phathom), Voquezna's sales surged by 217%, rising from 55.3 million dollars in 2024 to 175.1 million dollars last year. This year, the company posted sales of 132.58 million dollars in the first half alone, expected to significantly exceed last year’s results. As a result, substantial opportunities remain for Korean companies entering the market as latecomers.


The challenge lies in expanding the prescription base. Unlike in Korea, low-cost generic PPIs are well established as first-line therapies in the U.S., making it difficult to extend prescriptions to patients with mild and non-erosive disease. The monthly price of Voquezna is around 650 dollars, dozens of times higher than the 5 to 30 dollars for generic PPIs. For this reason, many insurers require “step therapy” and prior authorization, only covering P-CABs for patients who have first tried PPIs. The American Gastroenterological Association (AGA) also advises against using P-CABs as a uniform first-line treatment for non-erosive reflux disease or mild erosive esophagitis, citing cost and accessibility concerns.


Ultimately, experts note that Korean companies’ success in the U.S. will depend as much on pricing and insurance strategies as clinical efficacy. Phathom plans to initiate a Phase 3 trial this year to study “as-needed” dosing of Voquezna, i.e., taking the drug only when symptoms occur. The strategy is to capitalize on the quick onset of P-CABs to reduce dosing frequency and lessen the financial burden on patients with mild symptoms. K-CAB, meanwhile, was the first P-CAB to demonstrate superiority over PPI in U.S. Phase 3 trials, securing persuasive evidence to win over insurers.



One industry insider commented, “Phathom’s massive investment in ‘as-needed’ clinical trials for Voquezna is because capturing the mild patient segment is crucial for blockbuster growth. The key challenge for Korean companies will be convincing U.S. insurers and patients with mild symptoms to choose P-CABs over the inexpensive PPIs that have been used for decades.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing